Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer with limited treatment options. Tumor growth and relapse of TNBC are driven by breast cancer stem cells, and improved therapies that can eliminate those hardy cells are urgently needed. Researchers from the University of Frieburg discovered that coordinated differentiation and changes in the metabolism of breast cancer stem cells make them invisible for…

Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

Tablet-based diagnostics - 12/04/2023

TuCAN - innovative diagnostic procedure for neuropsychiatric disorders

Neuropsychiatric disorders are often diagnosed late and have a negative impact on quality of life. Diagnosing the disease at an early stage is vital to be able to help those affected by offering them treatment adapted to their specific requirements. This is what the TuCAN project in Tübingen aims to achieve through the early and differential diagnosis of neuropsychiatric disorders.

A key enzyme in sugar metabolism is inactivated particularly easily and efficiently by oxidative stress. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now shown that with this oxidation, cells switch to an alternative sugar breakdown pathway and can thus escape oxidative stress. Cancer cells in particular benefit from this mechanism, which can also protect them from therapy-related damage.

Inovedis GmbH’s innovative implant - 28/03/2023

Next-generation minimally invasive shoulder surgery

The treatment of shoulder injuries such as rotator cuff tears is one of the most common orthopaedic interventions. It is therefore quite surprising that the surgical procedure has not changed much for decades - although it is relatively complicated. The start-up Inovedis has now developed a completely new surgical technique based on an implant that can be performed simply, safely, quickly and cost-effectively with minimal stress for patients.

Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.

Review - 09/02/2023

5th Gene Technology Report – a critical observation of a cutting-edge technology

The societal importance of genetic technologies was demonstrated during the coronavirus pandemic, when it was possible to rapidly develop suitable vaccines thanks to genetic engineering methods. As a result, the Fifth Gene Technology Report published in autumn 2021 reads like a validation of many years of work, as well as making it clear that the will to continue the detailed long-term monitoring is very much present.

Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.

With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

Value-based healthcare - 11/01/2023

High-quality healthcare pays off

High-quality medical treatment is not only worthwhile for ill persons. The Division of Health Economics at the German Cancer Research Center in Heidelberg, headed up by Prof. Dr. Michael Schlander, together with researchers from Dresden, has carried out a cost-effectiveness analysis that shows that certified colon cancer centres provide not only better but also more cost-effective care than other clinics.

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

Neurodegenerative diseases - 12/12/2022

Blood-based biomarkers allow the early prediction of Alzheimer's risks

Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

What a success for Ulm University and its medical centre! The German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) extends the Collaborative Research Centre (CRC) on Trauma Medicine for the second time. The third funding phase infuses the CRC 1149 'Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma' with 11.1 million euros.

Start-up Actimi GmbH - 23/11/2022

Real-time telemonitoring of heart failure

Improved quality of life for patients and lower costs for health insurers: these are the advantages of telemonitoring patients with advanced heart failure. The Stuttgart-based start-up Actimi offers an all-in-one platform for those who treat and those who suffer from the disease.

DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.

MEDICA and COMPAMED continue to develop in an extremely vital manner. The world's leading medical trade fair and the international No. 1 for the medical technology supply sector once again impressively underscored their positive results from the previous year with strong numbers – despite continuing adverse conditions. A significant increase in bookings on the part of the exhibiting companies was followed after four days by a marked increase…

Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.

Viral cancer therapy - 26/10/2022

Therapeutic viruses against tumours and metastases

Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial.

Hummingbird Diagnostics GmbH - 22/09/2022

The great potential of blood-based microRNA analyses

"The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.

With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

Article - 14/09/2022

Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy

Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.

Dossier - 08/09/2022

Imaging methods in medical diagnostics

Many different imaging methods are available these days and are used in almost all medical disciplines to visualise disease-related changes. Depending on the problem and the clinical picture, very different structural and functional parameters can be visually recorded for diagnosis and used for therapy.

Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.

Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.

A centre for model-based artificial intelligence has been set up at Heidelberg University to link mathematical modelling methods with information processing in neuronal networks. The Carl Zeiss Foundation (CZS) is funding the CZS Heidelberg Center for Model-Based AI with five million euros over a period of six years.

RHEACELL GmbH - 28/07/2022

Innovative stem cell therapy for chronic wounds

Non-healing, chronically inflamed wounds can be very painful and carry the risk of serious infections. The Heidelberg company RHEACELL has developed a unique drug based on ABCB5-positive mesenchymal stem cells that helps reprogramme the relevant immune cells and promote healing.

AaviGen GmbH: Hope for heart failure - 14/07/2022

Gene therapy for weakened hearts

Treating a weak heart – for example after a heart attack – at the GP’s surgery with a single intravenous injection, without causing serious side effects: what sounds almost too good to be true is actually already under development. The Heidelberg-based biotech company AaviGen is working on a platform technology based on adeno-associated viruses that can help introduce therapeutic genes in a highly specific way into diseased heart muscle cells.

Biotech in outer space - 06/07/2022

yuri, a space start-up: weightlessness for commercial research

Growing cells without the effect of gravity could revolutionise drug development. A start-up called yuri on Lake Constance enables made-to-measure experiments on the ISS for stem cells, artificial organs, surfaces and materials. On board the next mission are some mini-cell labs from Berlin's Charité and Goethe University Frankfurt.

Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

COVIC-19 clinical trial - 07/04/2022

Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity

Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.

SolidCAR-T project - 15/03/2022

Modular ‘mini-factories’ for decentralised production of CAR T cells

Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

Biosensor for whole blood and exhaled breath analysis - 02/02/2022

Antibiotic detection from whole blood or exhaled breath possible

Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.

microRNA as a prognostic biomarker - 13/01/2022

Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.

Dossier - 16/12/2021

Advanced therapy medicinal products: gene and cell therapies

Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.